CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: A systematic review and meta-analysis

Journal of Geriatric Cardiology

Volumn 10, Issue 3, 2013, Pages 258-266

  Chen, Jia Yuan ^a   Zhang, Ai Dong ^a   Lu, Hong Yan ^a   Guo, Jun ^a   Wang, Fei Fei ^a   Li, Zi Cheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

Atrial fibrillation; CHA2DS2 VASc; CHADS2; Meta analysis; Prediction; Stroke

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CHA2DS2 CHA 2 DS 2 VASC SORE; CHADS2 SCORE; CLINICAL ASSESSMENT TOOL; COCHRANE LIBRARY; DATA EXTRACTION; EMBASE; ENGLISH AS A SECOND LANGUAGE; HEART ATRIUM FIBRILLATION; HUMAN; LOW RISK POPULATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MODERATE RISK POPULATION; QUALITY CONTROL; RISK; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 84885794513     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2013.03.004     Document Type: Article

References (21)

1. [No authors listed]. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
2. Lip GY, Edwards SJ. Stroke prevention with aspirin warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A system review and meta-analysis. Thromb Res 2006; 118: 321-333.
3. Gage BF, Waterman AD, Shannon W, et al. validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 2001, 285: 2864-2870.
4. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
5. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012; 14: 1385-1413.
6. McGinn TG, Guyatt GH, Wyer PC, et al. Users'guides to the medical literature: literature: XXII: how to use articles about clinical decision rules. J Am Med Assoc 2000; 284: 79-84.
7. Thompson SG, Higgins JPT. How should meta - regression analyses be undertaken and interpreted? Statist Med 2002, 21: 1559-1573.
8. Sharp S. she23: Meta-analysis regression. Stata Technical Bulletin (STB), 1998, 42: 16-22. http://onlinelibrary.wiley.com/doi/10.1002/sim.1187/full).
9. Poli D, Lip GY, Antonucci E, et al. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. J Cardiov-asc Electrophysiol 2011; 22: 25-30.
10. Lip GY, Frison L, Halperin JL. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738.
11. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342: d124.
12. Lin LY, Lee CH, Yu CC, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation - A nation wide database analysis. Atherosclerosis 2011; 217: 292-295.
13. Sandhu RK, Bakal JA, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: the risk - treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 2011; 97: 2046-2050.
14. Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9: 39-48.
15. Friberg L, Rosenqvist M, Lip GY, et al. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 12: 1500-1510.
16. Lee BH, Park JS, Park JH, et al. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS2 score 1. J Cardiovasc Electrophysiol 2010; 21: 501-507.
17. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke inpatients with atrial fibrillation and a CHADS2 score = 1. Thromb Haemost 2010; 103: 833-840.
18. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-2692.
19. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006: 447-451.
20. Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: the Belgrade Atrial Fibrillation Study. Circ Arrhythm Electrophysiol 2012; 5: 319-326.
21. Boriani G, Botto GL, Padeletti L, et al. Italian AT-500 Registry Investigators. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 2011; 42: 1768-1770.